The emerging role for chemokines in epilepsy

  title={The emerging role for chemokines in epilepsy},
  author={Paolo Francesco Fabene and Placido Bramanti and Gabriela Constantin},
  journal={Journal of Neuroimmunology},

Figures from this paper

Chemokines as new inflammatory players in the pathogenesis of epilepsy
Leukocyte trafficking mechanisms in epilepsy.
Immunity and Inflammation in Epilepsy.
There is increasing knowledge supporting a role of specific inflammatory mediators and immune cells in the generation and recurrence of epileptic seizures, as well as in the associated neuropathology and comorbidities.
Brain Infiltration of Leukocytes Contributes to the Pathophysiology of Temporal Lobe Epilepsy
Together, the concerted action of adaptive and innate immunity triggered locally by intrahippocampal kainate injection contributes seizure-suppressant and neuroprotective effects, shedding new light on neuroimmune interactions in temporal lobe epilepsy.
The role of inflammation in the development of epilepsy
Understanding the neurobiology of inflammation in epileptogenesis will contribute to the development of new biomarkers for better screening of patients at risk for epilepsy and new therapeutic targets for both prophylaxis and treatment of epilepsy.
The Neuroinflammatory Role of Pericytes in Epilepsy
In vitro and in vivo studies have highlighted the potential of pericytes as a therapeutic target for seizure disorders, and it is shown that they respond more sensitively to proinflammatory cytokines than microglia and can also activatemicroglia.
Cytokines and Neurodegeneration in Epileptogenesis
Increasing experimental and clinical data suggest the influence of peripheral inflammation on epileptogenesis, and studies focused on the molecular markers of neuroinflammation are of great value and may help deepen the knowledge about epilepsy, leading to the discovery of new drugs.


A role for leukocyte-endothelial adhesion mechanisms in epilepsy
Leukocyte-endothelial interaction is suggested as a potential target for the prevention and treatment of epilepsy by showing that seizures induce elevated expression of vascular cell adhesion molecules and enhanced leukocytes rolling and arrest in brain vessels mediated by the leukocyte mucin P-selectin glycoprotein ligand-1.
Brain Inflammation in Epilepsy: Experimental and Clinical Evidence
The possibility that inflammation may be a common factor contributing, or predisposing, to the occurrence of seizures and cell death, in various forms of epilepsy of different etiologies is discussed.
Immunology: Barrier to electrical storms
A new study using two-photon fluorescence microscopy suggests cytotoxic T lymphocytes can be seen recruiting monocytes and neutrophils to the meninges at the blood–brain border, which raises new questions, including the mechanism of cell recruitment and how the cells produce such damage in meningitis.
Chemokines in and out of the central nervous system: much more than chemotaxis and inflammation
Actions of chemokines and the interaction with specific receptors go beyond their original, defined role of recruiting leukocytes to inflamed tissues and are proposed to propose novel functions ofChemokine receptors during demyelination/remyelination, and developmental processes.
Angiogenesis is associated with blood-brain barrier permeability in temporal lobe epilepsy.
It is suggested that the persistent leakage of serum IgG in the interstitial space and their uptake by neurons may participate in hypoperfusion and in neuronal dysfunction occurring in TLE.
Pro-inflammatory cytokines and their effects in the dentate gyrus.
TGF-beta receptor-mediated albumin uptake into astrocytes is involved in neocortical epileptogenesis.
It is proposed that the above-described cascade of events following common brain insults leads to brain dysfunction and eventually epilepsy and suggest TGF-betaRs as a possible therapeutic target.
Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients.
The results imply pathogenic roles for specific chemokine-chemokine receptor interactions in MS and suggest new molecular targets for therapeutic intervention.
CCL19 is constitutively expressed in the CNS, up-regulated in neuroinflammation, active and also inactive multiple sclerosis lesions